<DOC>
	<DOC>NCT00373542</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of ropinirole CR-RLS in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance and period limb movements during sleep.</brief_summary>
	<brief_title>12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Inclusion criteria: provided written informed consent. Diagnosed with primary RLS using the International RLS Study Group Diagnostic Criteria with a total score of 20 or greater on the International RLS (IRLS) Rating Scale and significant sleep disturbance indicated on Item 4 of the IRLS rating scale. Have evening and nighttime symptoms of RLS, significant sleep impairment due to RLS symptoms, and symptoms requiring treatment prior to bedtime, but no earlier than 5:00PM. Sleep efficiency &lt;85% OR Latency to persistent sleep &gt;20 minutes. Exclusion criteria: Secondary RLS Primary sleep disorder Have any medical conditions that may impact efficacy assessments or that may present a safety concern. Pregnant or lactating or women of childbearing potential who are not practicing an acceptable method of birth control. Use of any prohibited medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>ropinirole</keyword>
	<keyword>polysomnography</keyword>
	<keyword>RLS</keyword>
	<keyword>PSG</keyword>
</DOC>